Alpha Cognition has reported positive top line data from the BEACON real-world study assessing provider-reported outcomes for mild-to-moderate Alzheimer’s disease treated with Zunveyl. The post Alpha Cognition announces top-line data in BEACON study for Alzheimer’s appeared first on Clinical Trials Arena .